Incidence of Haemophilus influenzae Type b Disease in The Gambia 14 Years after Introduction of Routine Haemophilus influenzae Type b Conjugate Vaccine Immunization

Child Survival Theme, Medical Research Council Unit, The Gambia.
The Journal of pediatrics (Impact Factor: 3.79). 07/2013; 163(1 Suppl):S4-7. DOI: 10.1016/j.jpeds.2013.03.023
Source: PubMed


Haemophilus influenzae type b (Hib) conjugate vaccine was first introduced in Africa in The Gambia in 1997 as a primary 3-dose course in infancy with no booster, and was followed by the disappearance of invasive Hib disease by 2002. A cluster of cases detected non-systematically in post-infant children in 2005-2006 raised the question of the need for a booster dose. The objective of this study was to determine the incidence of invasive Hib disease in Gambian children 14 years after the introduction of Hib conjugate vaccine.
This hospital-based clinical and microbiological Hib disease surveillance in 3 hospitals in the western region of The Gambia was undertaken between October 2007 and December 2010 applying the same methods used in a previous Hib vaccine effectiveness study in 1997-2002.
The annual incidences of Hib meningitis and all invasive Hib disease in children aged <5 years remained below 5 cases per 100 000 children during 2008-2010. The median age of patients with any invasive Hib disease was 5 months.
Hib conjugate vaccination as a primary 3-dose course in The Gambia remains highly effective in controlling invasive Hib disease, and current data do not support the introduction of a booster dose.

Download full-text


Available from: Claire Oluwalana, Feb 06, 2015
Show more

We use cookies to give you the best possible experience on ResearchGate. Read our cookies policy to learn more.